Clinical trial NCT03058497: Laminar Airflow in Severe Asthma for Exacerbation Reduction
Official title: A Multi-centre Randomised, Double Blind, Placebo-controlled, Parallel Group Trial of the Effectiveness of the Nocturnal Use of a Temperature Controlled Laminar Airflow (TLA) Device (Airsonett®) in Adults With Poorly-controlled, Severe Allergic Asthma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Asthma
Lead sponsor: Portsmouth Hospitals NHS Trust
Sponsor class: OTHER_GOV
Collaborators: name: University of Oxford
First posted: 2017-02-23
Enrollment: 240
Sex: ALL
Minimum age (years): 16
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To ascertain whether home-based nocturnal TLA usage over a 12 month period can reduce exacerbations and improve asthma control and quality of life as compared to placebo, whilst being cost-effective and acceptable to adults with poorly-controlled, severe allergic asthma.

Detailed description: We will include 222 adults, half of whom will be given a TLA device that is working, and the other half will be given a device which has been inactivated (the filtering process will be switched off, although the participants will not be able to tell that this has occurred). Which participant receives the working or deactivated device will be decided by a random process and will be unknown to the researcher and the participant. An engineering team from the manufacturer will install the device in the participants' home at the beginning of the study and be available throughout the study period to deal with any queries.

All participants will continue receiving their usual treatments. Participants will be in the study for 12 months, and will report their asthma attacks to the trial team whenever they occur during this period. In addition, they will visit the trial team 4 times (after 3, 6, 9 and 12 months) to assess their asthma control and quality of life. At the end of the trial, we will invite participants at each site to join a group discussion where researchers will explore the participant's thoughts about the TLA device. At the end of their participation in the trial, all participants who have used the device for more than 6 months, regardless of their initial study group, will be offered the opportunity to keep an active device in their home free of charge for a further four years.

Eligibility criteria: Inclusion Criteria:

- A clinical diagnosis of asthma for ≥6 months with either: Airflow variability Airway reversibility Airway hyper-responsiveness

* Requirement for high-dose inhaled corticosteroids (ICS) (≥1000μg/day beclomethasone (BDP) or equivalent
* Poorly controlled asthma demonstrated by BOTH

  ≥2 severe asthma exacerbations, ACQ (7-point) score \>1 at Screening Visit 1 and Randomisation Visit 2
* Atopic status
* Exacerbation free
* Able to use the TLA device during sleep on at least five nights per week
* Able to understand and give written informed consent prior

Exclusion Criteria:

* Current smokers or ex-smokers abstinent for \<6months
* Ex-smokers with ≥15 pack year smoking history
* Partner who is a current smoker and smokes within the bedroom where the TLA device is installed
* TLA device cannot be safely installed within the bedroom
* Intending to move out of study area within the follow-up period
* Documented poor treatment adherence
* Occupational asthma with continued exposure to known sensitising agents in the workplace
* Previous bronchial thermoplasty within 12 months of randomisation
* Treatment with Omalizumab (anti-IgE) within 120 days of randomisation
* Using long-term oxygen, Continuous Positive Airway Pressure (CPAP) or Non-Invasive Ventilation (NIV)
* Presence of clinically significant lung disease other than asthma, including smoking-related chronic obstructive pulmonary disease (COPD), bronchiectasis associated with recurrent bacterial infection, allergic bronchopulmonary aspergillosis (mycosis), pulmonary fibrosis, sleep apnoea, pulmonary hypertension, or lung cancer,
* Patients currently taking part in other interventional respiratory clinical trials

Primary outcomes:
measure: Exacerbation frequency
timeFrame: 12 months
Secondary outcomes:
measure: Asthma Control
timeFrame: 12 months
measure: Treatment effect on quality of Life
timeFrame: 12 months
measure: Evaluate the device
timeFrame: 12 months
measure: NHS Costs
timeFrame: 12 months
measure: NHS Costs
timeFrame: 12 months
Other outcomes:
Locations:
city: Portsmouth
country: United Kingdom
facility: Portsmouth Hospital NHS Trust
state: UK
Study officials:
affiliation: Portsmouth Hospitals NHS Trust
name: Anoop[ Chauhan
role: STUDY_CHAIR
References: